How States Control Medicaid Generic Drug Costs: Policies, Strategies & Challenges

Prescription drugs are a massive line item in any healthcare budget, but for Medicaid programs across the United States, the pressure is particularly intense. You might assume that because generic drugs are cheap, they aren't a major financial concern. The reality is quite different. While generics make up nearly 85% of all prescriptions filled in Medicaid, they account for only about 16% of total drug spending. That sounds efficient, right? It is-until you consider that even small percentage increases in generic prices can balloon into billions of dollars in costs when applied to millions of patients.

States are not just sitting back and letting federal rules dictate their spending. They are actively fighting to control these costs using a mix of price caps, rebate negotiations, and supply chain maneuvers. But it’s a delicate balancing act. Push too hard on price, and manufacturers might stop making the drug entirely. Let up, and budgets blow out. So, how are states navigating this minefield? Let’s look at the specific strategies they’re deploying to keep costs down without cutting off patient access.

The Federal Foundation: MDRP and Its Limits

To understand what states are doing, you first have to understand what they *can’t* easily change. The backbone of Medicaid drug pricing is the Medicaid Drug Rebate Program (MDRP), which is a federal program requiring manufacturers to pay rebates to Medicaid in exchange for coverage of their products. Established by the Omnibus Budget Reconciliation Act of 1990 (OBRA '90), this program sets the floor for drug pricing.

For generic drugs, the math is rigid. Manufacturers must pay a base rebate equal to 13% of the Average Manufacturer Price (AMP) or the difference between the AMP and the best price they offer to anyone else, whichever is higher. This formulaic approach leaves states with very little room to negotiate better deals for generics compared to brand-name drugs, where supplemental rebates are common.

This lack of flexibility frustrates state officials. Dr. Mark Duggan from the Stanford Institute for Economic Policy Research pointed out in early 2025 that reforming these rebate structures could save billions. However, changing federal law is slow. In the meantime, states are looking for loopholes and alternative levers to pull within the existing framework.

Maximum Allowable Cost (MAC) Lists: The Primary Lever

If MDRP rebates are the foundation, then Maximum Allowable Cost (MAC) lists are the primary tool states use to trim fat. A MAC list is essentially a cap on what Medicaid will reimburse pharmacies for generic drugs. If a pharmacy pays $5 for a box of antibiotics, but the state’s MAC list says the maximum allowable cost is $4.50, Medicaid pays $4.50.

As of 2024, 42 states maintain these MAC lists. The strategy is simple: force competition among generic suppliers and capture the lowest available market price. Thirty-one of these states update their lists quarterly or more frequently to keep pace with fluctuating wholesale prices.

However, this system isn't perfect. The National Community Pharmacists Association surveyed over 1,200 independent pharmacies in late 2024 and found that 74% experienced delayed payments or claim rejections due to discrepancies in these MAC lists. When prices drop rapidly, states sometimes fail to update the MAC cap quickly enough, leaving pharmacies stuck holding inventory they can't get reimbursed for properly. Conversely, if the MAC is set too low during a shortage, pharmacies may refuse to stock the drug because they lose money on every sale.

Taming the Middlemen: PBM Oversight

You can’t talk about drug costs without talking about Pharmacy Benefit Managers (PBMs). These companies sit between insurers (like Medicaid) and pharmacies, negotiating prices and managing formularies. For years, their inner workings were opaque. States suspected that PBMs were keeping a large portion of the rebates and discounts rather than passing them on to Medicaid programs.

In response, there has been a wave of legislative action. In 2024 alone, 30+ states introduced legislation to counteract PBM restrictions. Twenty-seven states implemented new transparency requirements, with 19 now mandating that PBMs disclose the actual acquisition costs of generic drugs. States like Delaware and Missouri have gone further, passing laws to shape the 340B policy landscape, which affects how safety-net providers purchase drugs.

The goal here is visibility. By forcing PBMs to show their cards, states hope to negotiate harder or even bypass certain PBM services for generic drugs, where the administrative overhead often outweighs the value added. Thirty-three states currently contract with major PBMs like Magellan, OptumRx, or Conduent, but the relationship is becoming increasingly adversarial as states demand more accountability.

Price Gouging Protections and PDABs

What happens when a generic drug price spikes overnight without any clear reason? This is known as price gouging, and it’s a nightmare for budget planners. To combat this, some states have taken aggressive stances. Maryland, for example, enacted legislation in 2020 that penalizes manufacturers for unjustified price increases on generic drugs unless they can provide new clinical data justifying the hike.

A broader trend is the rise of Prescription Drug Affordability Boards (PDABs). By 2024, nine states-including California, Colorado, and Maryland-had established these boards. While PDABs often focus on high-cost specialty drugs, their authority extends to monitoring and capping prices for off-patent generics as well. Minnesota, for instance, uses prices established in the Inflation Reduction Act as a guide for setting upper payment limits.

These measures send a strong signal to manufacturers: the era of unchecked price hikes is ending. However, the Pharmaceutical Care Management Association (PCMA) argues that such controls disrupt market mechanisms and could lead to reduced availability. It’s a classic tug-of-war between affordability and supply stability.

Supply Chain Resilience: Preventing Shortages

Cost control is useless if patients can’t get their medication. In 2023, 23 states reported shortages of critical generic medications, with each shortage lasting an average of 147 days. This highlights a critical vulnerability: the generic manufacturing sector is highly consolidated. According to FDA data, just three companies control 65% of the generic injectables market. When one of them has a production issue, the entire country feels it.

States are starting to treat supply chain resilience as part of cost containment. Why? Because treating patients for conditions that go unmanaged due to drug shortages is far more expensive than buying the drug upfront. Twelve states introduced legislation in 2024 to address shortages through strategic stockpiling and alternative sourcing. By 2026, NASHP forecasts that 22 states will have developed strategic stockpiling programs for critical generics.

Additionally, collaboration is key. Oregon and Washington led a multi-state purchasing pool to collectively negotiate supplemental rebates for 47 high-volume generic drugs. By banding together, smaller states gain the leverage usually reserved for national health systems, allowing them to secure better prices and guaranteed supply contracts.

Emerging Challenges: GLP-1s and Future Outlook

The landscape is shifting again with the rise of GLP-1 medications for obesity and diabetes. With average annual treatment costs around $12,000, these drugs pose a significant threat to state budgets. While not generics yet, their eventual entry into the generic market will be a huge event. Currently, 13 state Medicaid programs cover certain GLP-1s, usually with strict prior authorization.

A proposed federal rule requiring coverage of these drugs for obesity could add $1.2 billion annually to state Medicaid costs, according to KFF. As states prepare for this influx, they are refining their generic strategies to handle high-volume, high-demand drugs. The Congressional Budget Office predicts that state initiatives targeting generics could reduce spending by $3.8 billion annually by 2027. But they also warn that overly aggressive policies could backfire, reducing availability and increasing overall costs by 2.3% as patients switch to more expensive alternatives.

The future of Medicaid generic policies lies in balance. States must continue to innovate with MAC lists, PBM oversight, and collaborative purchasing while ensuring that the supply chain remains robust enough to meet patient needs. It’s a complex puzzle, but getting it right is essential for the sustainability of public healthcare.